VacZine Analytics  
MarketVIEW: Novel coronavirus [COVID-19] vaccines

Q3 2021
INTERACTIVE MODEL (.xls) is updated per order#

The novel coronavirus, SARS-CoV-2 emerged from Wuhan City, Hubei Province of China in late December 2019, causing a cluster of atypical pneumonia cases among stallholders at a seafood wholesale market. The resulting respiratory disease, later referred to as COVID-2019, was designated by the World Health Organisation (WHO) a Public Health Emergency of International Concern (PHEIC) on the 30th January 2020 and later a global pandemic by March 11th, 2020.

COVID-19 has affected ~190 countries/territories with greater than 182 million confirmed cases and close to 4 million deaths (as of July 1st 2021), mainly in the elderly and those with chronic underlying conditions. It is predicted that a large proportion of the global population will be infected with SARS-CoV-2 causing further excess morbidity, mortality and substantial economic loss. SARS-CoV-2 is related to other coronaviruses such as MERS-CoV (2012), SARS-CoV-1 (2003) and the endemic human betacoronaviruses OC43 and HKU1 which cause the common cold. New variants such as Delta continue to pose a threat to unvaccinated populations.

There is no specific treatment for COVID-19. Whether widespread herd immunity can be achieved is deeply controversial. Numerous efforts have been underway to develop new prophylatic vaccines and antiviral therapeutics to address the emergence of SARS-CoV-2. 4 Western vaccines (of 17 in use) have gained Emergency Use Approval (EUA) in selected nations and include Moderna Therapeutics (mRNA-1273), Pfizer/BioNTech (BNT162b2), Janssen (JNJ-78436735) and Oxford/AstraZeneca (AZD1222, ChAdOx1-nCOV-19). Two mRNA approaches have shown high efficacy for the primary and secondary endpoints set for the Phase III pivotal studies and are currently being used in mass vaccination programs with approximately 3.08 bn doses being administered to date (As of July 1st 2021, Our World in Data). Other vaccines from Novavax (NVX-CoV2373) and ROW producers (SinoPharm, Sinovac, SSI) have also shown Phase III efficacy. Boosters and multivalent strategies are now underway (mRNA-1273.351 and mRNA.211)

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation and INTERACTIVE MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic COVID-19 vaccine to 2045. The model has three detailed and fully adjustable deployment scenarios which include the major Western economies, emerging economies of SE Asia, LATAM and the Far East*. 'At risk' populations or identified target segments (based on latest understanding) are included. A review of competitor R&D activity is also provided along with a discussion of new product strategy, potential in the post-pandemic seasonal scenario along with pricing considerations.

Adjustable features of the MS-Excel model are:
» Launch date
» Target group sequence
» % vaccine coverage per target group
» % at risk/% private sector
» Seasonal price versus pandemic price
» Yearly or bi-yearly schedule [Forthcoming Versions]
» Number of boosters/per schedule

*63 countries, 15 are rolled up, other scenarios are global - all countries #subject to agreed specification and timeframe

>>Try a sample by Microsoft PowerBI


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV086 Click here>> CONTACT US
*This is a licensed product. Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase. Picture Credit: CDC (Unsplash)

Return to main list>> Questions about this report?

© 2020 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains